FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 226 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... November 12, 2019 Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells November 21, 2023 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... April 11, 2023 Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 Load more HOT NEWS ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March Man Gets His First Haircut In 15 Years To Join The... FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable...
